Scinai Immunotherapeutics, which focuses on developing inflammation and immunology biological products and providing CDMO services through its Scinai Bioservices business unit, established a U.S.-based subsidiary for its CDMO services. The new subsidiary, incorporated in Delaware, will operate under the name Scinai Bioservices.
Scinai launched its CDMO business unit earlier this year, which operates from the company’s site in Jerusalem. The facility includes 1,850 ft2 (approximately 20,000 m2) of clean rooms and laboratories. The CDMO has executed drug development projects for nine different biotech companies, including upstream and downstream process development, scaleup, analytical methods development and drug manufacturing for pre-clinical and clinical supplies. Additionally, the company has partnered with Ayana Pharma to provide liposomal encapsulated drug development.
“We are thrilled and energized by the opening of our new subsidiary in the U.S.,” said Amir Reichman, CEO of Scinai. “Last week, we signed our first contract with U.S. customer, Serpin Pharma, to support their clinical manufacturing. I believe that our expanded presence in the U.S. will significantly enhance the prospects of our CDMO unit.”
